Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/General Biotech
General Biotech · The big question

New acting FDA chief brings expected stability to biotech

STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief

STAT News1 min readAI-assisted summary
Editorial illustration for STAT+: ‘No drama’ Diamantas should serve biotech well as acting FDA chief
Editorial illustration

Summary

The Food and Drug Administration, the federal agency responsible for protecting public health, has a new leader. Following the resignation of Marty Makary, Kyle Diamantas has stepped in as the new acting commissioner. While leadership changes at major government agencies can sometimes cause uncertainty, experts expect this transition to be remarkably smooth.

Before taking on this top role, Diamantas served as the highest ranking food regulator within the agency. Industry watchers anticipate that his leadership will provide a calm, stabilizing environment for both the biotechnology sector and the investors who fund new medical treatments. Early signs suggest a drama-free tenure that will allow the agency to continue its vital regulatory work without major disruptions.

Why it matters.

Stable leadership at the Food and Drug Administration is crucial for the future of medicine. The agency oversees the approval of every new drug, medical device, and treatment that reaches patients. When the top office is running smoothly, biotechnology companies can plan their research and development more effectively, knowing that the regulatory process will remain consistent. This predictable environment helps secure the investment needed to bring lifesaving therapies to the public.

It is important to note that these early impressions come from an opinion-based industry newsletter rather than hard empirical data. There are no quantitative metrics available yet to predict exactly how Diamantas will govern the medical side of the agency given his background in food regulation. However, the current consensus points toward a steady and reliable transition period for the medical industry.

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
General Biotech

Maryland sets a $274 monthly price cap on the diabetes drug Ozempic

The state of Maryland is taking a major step to rein in the cost of prescription medications. The Maryland Prescription Drug Affordability Board recently decided to set a strict price limit on Ozempic, a widely used treatment for type 2 diabetes. By establishing what is known as an upper payment limit, the board aims to make the medication more affordable for state budgets. Under this new rule, the cost of Ozempic will be capped at $274 for a standard 30-day supply. To come up with this number, the board looked at the maximum fair price that Medicare currently pays for the drug and used it as a benchmark. State officials estimate that this single price cap will save Maryland about $5.8 million every year. However, everyday consumers will not see these savings immediately. The initial price cap is slated to take effect in January 2027, and it will strictly apply to state and local government health plans. This means the immediate financial relief is limited to public programs rather than individual pharmacy visits for the general public.

STAT News1 min read
General Biotech

FDA shakeups, safety warnings, and a promising obesity pill

The Food and Drug Administration is navigating major leadership transitions, with acting directors Tracy Beth Høeg and Katherine Szarama recently exiting their roles in top drug review offices. Amidst these changes, the agency is facing severe safety concerns regarding Tavneos, a rare disease medication from the pharmaceutical company Amgen. In Japan, twenty patients taking the drug have died, with most of these deaths linked to a severe liver condition called vanishing bile duct syndrome. Following these tragedies and allegations of manipulated clinical trial data, the FDA has asked Amgen to withdraw the drug in the United States, though it currently remains available on the market. In other medical developments, an experimental daily pill for obesity is showing significant promise. Vincentage Pharma reported that patients taking its drug VCT220 in a late-stage Chinese clinical trial lost about twelve percent of their body weight over a year, compared to just one percent for those taking a placebo. However, the drug is still experimental globally, and a broader Phase 2 study is underway with results not expected until late 2026. Meanwhile, the major drugmaker Regeneron has teamed up with an early-stage startup called Parabilis Medicines. They plan to develop new therapies known as "antibody-helicon conjugates," which are designed to reach and treat disease-causing proteins inside cells that conventional methods have traditionally found impossible to target.

BioPharma Dive2 min read
General Biotech

Physical decline starts at 35, but late-in-life exercise boosts fitness

A massive study tracking people in Sweden for almost 50 years has pinpointed exactly when our bodies start to lose their physical edge. Researchers discovered that overall fitness, physical strength, and muscle endurance quietly begin to slip around age 35. Rather than maintaining a slow and steady pace, the researchers noted that the rate of this physical decline actually speeds up as the years go by. However, the study offers a highly encouraging twist for older adults. Even if someone has been inactive for decades, deciding to adopt a physically active lifestyle later in life can still yield major benefits. The researchers found that these late starters actually improved their physical performance by up to 10 percent, proving that the human body remains responsive to exercise well into old age. While tracking individuals over a five-decade span is a remarkable scientific achievement, there are a few limitations to keep in mind. The research is based entirely on a Swedish cohort, so it is unclear if these exact timelines apply to more diverse global populations. Additionally, the initial data does not specify the exact number of participants or the specific medical tests used to measure their fitness levels.

Science Daily1 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
New acting FDA chief brings expected stability to biotech — Daily Strand